Last Updated: November 19, 2026

JOENJA Drug Patent Profile

« Back to Dashboard


When do Joenja patents expire, and when can generic versions of Joenja launch?

Joenja is a drug marketed by Pharming and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in JOENJA is leniolisib phosphate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the leniolisib phosphate profile page.

DrugPatentWatch® Generic Entry Outlook for Joenja

Joenja will be eligible for patent challenges on March 24, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 19, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for JOENJA?
  • What are the global sales for JOENJA?
  • What is Average Wholesale Price for JOENJA?
Summary for JOENJA
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JOENJA
Generic Entry Date for JOENJA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for JOENJA

JOENJA is protected by one US patents and five FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of JOENJA is ⤷  Start Trial.

This potential generic entry date is based on patent 8,653,092.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharming JOENJA leniolisib phosphate TABLET;ORAL 217759-002 Sep 11, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharming JOENJA leniolisib phosphate TABLET;ORAL 217759-001 Mar 24, 2023 RX Yes Yes 8,653,092 ⤷  Start Trial Y Y ⤷  Start Trial
Pharming JOENJA leniolisib phosphate TABLET;ORAL 217759-003 Sep 11, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharming JOENJA leniolisib phosphate TABLET;ORAL 217759-001 Mar 24, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pharming JOENJA leniolisib phosphate TABLET;ORAL 217759-002 Sep 11, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JOENJA

When does loss-of-exclusivity occur for JOENJA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4970
Estimated Expiration: ⤷  Start Trial

Patent: 5927
Estimated Expiration: ⤷  Start Trial

Patent: 8919
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 11275777
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2013000275
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 02132
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 13000033
Estimated Expiration: ⤷  Start Trial

China

Patent: 2971317
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 70566
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 130004
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0140778
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 15457
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 90974
Estimated Expiration: ⤷  Start Trial

Dominican Republic

Patent: 013000027
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 13012420
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 4123
Estimated Expiration: ⤷  Start Trial

Patent: 1291317
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 90974
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 0265013
Estimated Expiration: ⤷  Start Trial

Guatemala

Patent: 1300009
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 79966
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 3795
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 70842
Estimated Expiration: ⤷  Start Trial

Patent: 13535411
Estimated Expiration: ⤷  Start Trial

Jordan

Patent: 39
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 2026527
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 6026
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 12015088
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 361
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 4302
Estimated Expiration: ⤷  Start Trial

Nicaragua

Patent: 1300002
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 130650
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 013500031
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 90974
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 90974
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 490
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 6187
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 90974
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1209117
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1560066
Estimated Expiration: ⤷  Start Trial

Patent: 130041068
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 94718
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1206930
Estimated Expiration: ⤷  Start Trial

Patent: 34145
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 12000578
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 2517
Estimated Expiration: ⤷  Start Trial

Uruguay

Patent: 486
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JOENJA around the world.

Country Patent Number Title Estimated Expiration
Argentina 084970 ⤷  Start Trial
Argentina 115927 ⤷  Start Trial
Argentina 118919 ⤷  Start Trial
Australia 2011275777 ⤷  Start Trial
Brazil 112013000275 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for JOENJA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2590974 301386 Netherlands ⤷  Start Trial PRODUCT NAME: LENIOLISIB, DESGEWENST IN DE VORM VAN EEN N-OXIDE OF FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, IN HET BIJZONDER LENIOLISIBFOSFAAT; REGISTRATION NO/DATE: EU/1/26/2034 20260521
2590974 CA 2026 00029 Denmark ⤷  Start Trial PRODUCT NAME: LENIOLISIB, EVENTUELT I FORM AF ET N-OXID ELLER FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LENIOLISIBPHOSPHAT.; REG. NO/DATE: EU/1/26/2034 20260521
2590974 C20265013 Finland ⤷  Start Trial
2590974 2026C/725 Belgium ⤷  Start Trial PRODUCT NAME: LENIOLISIB, DESGEWENST IN DE VORM VAN EEN N-OXIDE OF FARMACEUTISCH AANVAARDBAARZOUT ERVAN, IN HET BIJZONDER LENIOLISIBFOSFAAT; AUTHORISATION NUMBER AND DATE: EU/1/2026/2034 20260521
2590974 PA2026527 Lithuania ⤷  Start Trial PRODUCT NAME: JOENJA - LENIOLISIBAS; REGISTRATION NO/DATE: EU/1/26/2034 20260521
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Joenja Market Dynamics and Financial Trajectory

Last updated: October 9, 2026

Joenja (leniolisib) is Pharming Group N.V.’s targeted treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS. FDA approval in March 2023 created the first U.S. commercial product specifically indicated for APDS in patients aged 12 years and older. The product’s market is small but highly concentrated, with orphan-drug pricing, limited direct competition, and substantial dependence on diagnosis, payer access, and international expansion.

Joenja is positioned as Pharming’s second commercial growth product alongside Ruconest. Its financial trajectory depends less on broad prescription volume than on the company’s ability to identify undiagnosed APDS patients, secure reimbursement, expand the label, and commercialize in Europe and other regulated markets.

What is Joenja and which patients does it treat?

Joenja is an oral selective phosphoinositide 3-kinase delta inhibitor. It is approved in the United States for adults and adolescents at least 12 years old with APDS, a primary immunodeficiency caused by activating mutations in the PIK3CD gene or inactivating mutations in the PIK3R1 gene.

APDS can cause:

  • Recurrent respiratory and other infections
  • Enlarged lymph nodes and spleen
  • Chronic lung disease
  • Autoimmune and inflammatory complications
  • Increased risk of lymphoma and other malignancies
  • Impaired growth and developmental complications

The FDA approval was based primarily on a randomized clinical study using lymphoproliferation, measured through changes in lymph node volume, as a key efficacy endpoint. The FDA label also identifies improvements in immune-system biomarkers, including phosphorylated AKT levels.[1]

What is the approved Joenja dosage?

The recommended dose is 70 mg orally twice daily for patients weighing at least 45 kg. Patients weighing between 35 kg and less than 45 kg receive 50 mg twice daily. The product is administered with or without food, subject to the prescribing information’s interaction and administration requirements.[1]

How large is the Joenja market?

The addressable APDS market is an ultra-rare disease market. Published prevalence estimates generally place APDS at approximately one to two patients per million people, although the actual patient population is likely underdiagnosed.[2]

Market factor Commercial implication
Disease prevalence Very low, limiting absolute patient volume
Diagnosis Genetic testing and specialist referral are required
Treatment need High, because APDS causes progressive immune and organ damage
Competition Limited direct competition for APDS
Pricing Orphan-drug pricing supports high revenue per treated patient
Reimbursement Prior authorization and documentation requirements are material
Geographic expansion Important because U.S. patient volume alone is limited
Duration of therapy Generally chronic, supporting recurring revenue

Pharming has estimated the global APDS population at several thousand patients, with a smaller subset currently diagnosed and eligible for treatment. The principal commercial opportunity is therefore not mass-market penetration. It is the conversion of diagnosed patients, systematic identification of undiagnosed patients, and expansion into additional age groups and geographies.

What is Joenja’s financial trajectory?

Joenja generated its first commercial revenue in 2023 after U.S. launch. Pharming reported approximately $10 million in Joenja revenue during the initial launch period. The result reflected a partial year of commercial sales, patient identification, payer onboarding, and the time required to place patients on therapy.[3]

The product’s revenue growth accelerated in 2024 as Pharming expanded its U.S. commercial infrastructure and increased patient starts. Public company reporting indicates that Joenja revenue reached approximately $60 million in 2024, representing a several-fold increase from the initial launch year.[4]

Fiscal period Joenja commercial status Approximate revenue
2022 Pre-commercial $0
2023 U.S. launch and initial patient starts About $10 million
2024 Broadening U.S. uptake and recurring treatment revenue About $60 million
2025 onward Expansion-driven growth phase Dependent on patient identification, reimbursement and international launches

The early revenue curve is consistent with an ultra-rare disease launch. Revenue growth initially comes from new patient starts. As the treated base expands, recurring revenue becomes the primary driver, subject to discontinuations, safety events, reimbursement changes, and mortality associated with the underlying disease.

What is the revenue contribution relative to Ruconest?

Ruconest remains Pharming’s larger commercial product and the company’s primary revenue base. Joenja is strategically important because it diversifies Pharming beyond hereditary angioedema and provides exposure to a chronic immunology market with high annual treatment value.

Factor Joenja Ruconest
Active ingredient Leniolisib Recombinant C1 esterase inhibitor
Primary indication APDS Acute hereditary angioedema attacks
Treatment pattern Chronic therapy Episodic treatment
Revenue model Recurring patient revenue Attack frequency and product utilization
Main commercial risk Diagnosis and reimbursement Competition, supply and attack-treatment demand
Strategic role Growth and diversification Established revenue foundation

Joenja’s financial significance is increasing even though Ruconest remains larger. A continued rise in Joenja revenue can reduce Pharming’s dependence on an episodic product and improve revenue predictability.

What price does Joenja command?

Joenja launched at an annual wholesale acquisition cost of roughly $500,000 per patient, subject to payer discounts, rebates, assistance programs, and actual treatment duration. The economic value of the product is based on the severity of APDS, the cost of recurrent infections and hospital care, and the potential to reduce long-term organ damage.

Net revenue per patient is lower than list price. The principal deductions are:

  • Commercial payer rebates
  • Medicaid and government-program discounts
  • Patient assistance
  • Specialty-pharmacy fees
  • Distributor deductions
  • Product returns and chargebacks

For financial modeling, gross list price should not be used as realized revenue. A practical model should apply a net-to-gross assumption and separately estimate treated patients, persistence, and geographic mix.

What is driving Joenja market growth?

How important is APDS diagnosis?

Diagnosis is the largest structural growth variable. APDS can resemble common variable immunodeficiency, autoimmune disease, chronic respiratory disease, or other primary immunodeficiencies. Genetic confirmation is required for treatment selection.

Pharming’s commercial strategy therefore depends on:

  1. Physician education among immunologists and geneticists.
  2. Testing of patients with severe or atypical immune dysregulation.
  3. Referral networks connecting community physicians with specialty centers.
  4. Coverage for genetic testing.
  5. Earlier identification of pediatric patients.

The addressable market can expand without any change in disease prevalence if diagnostic penetration improves.

What is the effect of label expansion?

The initial U.S. approval covers patients aged 12 years and older. Approval for younger children would materially expand the eligible population and could support earlier treatment before irreversible organ damage develops.

Label expansion also could include:

  • Additional age cohorts
  • European and other international approvals
  • Earlier-line treatment
  • Use in genetically confirmed subpopulations
  • Potential long-term complications associated with APDS

The commercial value of pediatric expansion would depend on regulatory data, dosing, formulation, and the ability to diagnose children through genetic testing.

What is the FDA regulatory status of Joenja?

The FDA approved Joenja on March 24, 2023, under the agency’s orphan-drug framework.[1] The approval made Joenja the first FDA-approved treatment specifically indicated for APDS.

The main U.S. regulatory protections are:

Protection Status
FDA approval March 24, 2023
Orphan-drug exclusivity Seven years from approval, generally extending through March 2030
New chemical entity exclusivity Not the principal commercial protection disclosed for the product
Pediatric exclusivity Depends on completion and acceptance of qualifying FDA pediatric studies
Biologic exclusivity Not applicable because Joenja is a small-molecule drug

Orphan-drug exclusivity prevents FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions. It does not prevent all forms of competition, including off-label use, different products, or products with non-identical active ingredients.

What patents protect Joenja?

Joenja’s commercial protection is based on a combination of patents, orphan-drug exclusivity, regulatory know-how, clinical data, manufacturing controls, and the difficulty of identifying eligible APDS patients.

The most important legal distinction is between:

  • Composition-of-matter patents covering leniolisib or related chemical structures
  • Salt, polymorph, or crystalline-form patents
  • Pharmaceutical-composition and formulation patents
  • Method-of-treatment patents for APDS
  • Manufacturing and process patents
  • Regulatory exclusivity under the Orphan Drug Act

The public commercial moat is stronger than a simple patent-count analysis suggests because APDS is a genetically defined ultra-rare disease and patient identification is concentrated in specialist centers.

What is the Orange Book status of Joenja?

Joenja is an FDA-approved small-molecule prescription drug and is subject to Orange Book patent and exclusivity analysis. The commercially relevant questions are whether Pharming or its licensors have listed patents, the expiration dates of those patents, and whether a future ANDA applicant would need to make Paragraph IV certifications.

A generic applicant would face three principal barriers:

  1. FDA orphan-drug exclusivity through approximately March 2030.
  2. Any unexpired listed patents covering leniolisib, its formulation, or approved use.
  3. Limited economic incentive to develop a generic for a very small patient population.

Orphan exclusivity does not eliminate Paragraph IV risk. A generic company could file an ANDA after the relevant exclusivity period and challenge listed patents before their expiration.

When does Joenja lose exclusivity?

The core U.S. orphan-drug exclusivity period runs for seven years from FDA approval, placing the expected endpoint around March 24, 2030.[1]

The practical timing of generic entry may differ because:

  • A patent may expire after orphan exclusivity.
  • A generic applicant may challenge a patent before its expiration.
  • The FDA may approve a different product for the same disease if statutory conditions are met.
  • Pediatric exclusivity could extend certain protections by six months if granted.
  • Litigation may delay or accelerate market entry.

The highest-probability generic-entry window is therefore after March 2030, subject to the Orange Book patent estate and any litigation settlement.

What Paragraph IV and litigation risks exist?

No major public Paragraph IV litigation involving an ANDA for Joenja had emerged during the initial commercial period covered by Pharming’s launch reporting. That is expected for a product with a small patient population and several years of orphan exclusivity remaining.

The risk profile changes as 2030 approaches. Potential challengers could include:

  • Specialty generic manufacturers
  • Large generic companies seeking high-value orphan products
  • Contract development and manufacturing organizations with formulation expertise
  • Companies developing alternative PI3K-delta inhibitors

A Paragraph IV filing would provide the first clear signal of a formal generic-entry strategy. A patent litigation settlement could establish an authorized-generic launch date earlier than full patent expiry, although no material public Joenja settlement had been reported in the initial launch period.

How strong is the Joenja patent estate?

Joenja has a strong commercial protection profile but a less transparent value proposition than a mass-market medicine with numerous Orange Book patents.

Strengths

  • Seven-year U.S. orphan exclusivity
  • First-mover position in APDS
  • Genetically defined patient population
  • Specialist prescribing concentration
  • High treatment value per patient
  • Clinical and diagnostic infrastructure that is difficult to replicate quickly
  • Potential international and pediatric expansion

Weaknesses

  • Small absolute market
  • Dependence on one active ingredient
  • Potentially limited generic economics after exclusivity
  • Need for continued patient finding
  • Exposure to payer scrutiny over a high annual price
  • Potential development of alternative immune-modulating treatments

The highest-value intellectual property is likely the combination of active-ingredient, formulation, and APDS treatment claims, while the strongest non-patent protection is the company’s diagnostic and commercial infrastructure.

Which companies compete with Joenja?

Joenja has no approved direct competitor specifically labeled for APDS in the United States. Competition comes from three categories.

Existing immune-modulating therapies

Patients may receive immunoglobulin replacement, immunosuppressants, antibiotics, hematopoietic stem-cell transplantation, or off-label targeted treatments. These products are substitutes in clinical practice but do not have the same approved APDS indication.

Pipeline PI3K-delta and immune therapies

Other PI3K-pathway inhibitors could compete if they demonstrate a favorable benefit-risk profile in APDS or related primary immunodeficiencies. The main competitive issue is not simply efficacy. It is the ability to achieve a suitable safety profile for chronic use.

Curative or disease-modifying approaches

Hematopoietic stem-cell transplantation can be considered in selected severe patients, particularly pediatric patients, but it carries significant procedural risk and is not a broad commercial substitute for chronic oral therapy.

What generic launch scenarios are most likely?

Scenario Timing Commercial effect
No early challenge After 2030 Gradual generic erosion
Patent challenge without settlement Before 2030 filing, launch dependent on litigation Potential sharp price and volume pressure
Authorized generic settlement Before or around patent expiry Earlier but controlled erosion
Competing branded therapy Before 2030 Pressure on new patient starts and payer positioning
Pediatric expansion Before 2030 Larger treated population and stronger revenue growth
Diagnostic stagnation Any time Revenue growth below epidemiological potential

Because Joenja is a chronic therapy for a small patient population, generic erosion may be slower in volume but substantial in price. Payers could direct patients toward a generic quickly if clinical substitution is straightforward.

What is the investment and commercial outlook?

The base-case commercial outlook is continued revenue growth through the second half of the decade, driven by:

  • U.S. patient identification
  • Higher treatment persistence
  • International approvals
  • Pediatric expansion
  • Greater genetic-testing adoption
  • Recurring revenue from the installed patient base

The principal downside is that the diagnosed patient pool may be smaller than projected. A high price can also delay payer approval or lead to restrictive utilization controls.

Joenja has meaningful strategic value for Pharming because it adds a chronic, specialty-immunology revenue stream to a business historically centered on Ruconest. The product is unlikely to become a mass-market blockbuster based on APDS prevalence alone. Its value lies in high revenue per patient, expansion of diagnosis, and the possibility of using the commercial platform for additional rare-disease products.

Key Takeaways

  • Joenja is the first FDA-approved treatment specifically indicated for APDS.
  • FDA approval occurred on March 24, 2023.
  • U.S. orphan-drug exclusivity is expected to run through approximately March 2030.
  • Joenja generated about $10 million in initial 2023 revenue and approximately $60 million in 2024 revenue based on Pharming reporting.
  • Growth depends primarily on diagnosis, patient starts, reimbursement, and geographic expansion.
  • The product has no approved direct APDS competitor in the United States.
  • Patent and regulatory protection provide a meaningful pre-2030 barrier, although orphan exclusivity does not eliminate all competitive pathways.
  • Pediatric approval and international commercialization are the largest identifiable upside drivers.
  • The main long-term risk is a limited diagnosed population combined with price pressure after exclusivity expiry.

FAQs

Is Joenja a biologic or a generic drug?

Joenja is a small-molecule oral drug containing leniolisib phosphate. It is not a biologic and would be subject to an ANDA pathway for a qualifying generic product.

Does Joenja require lifelong treatment?

APDS is a chronic genetic immune disorder, and Joenja is generally used as ongoing treatment. Actual duration depends on clinical response, tolerability, disease severity, transplantation decisions, and physician judgment.

Is Joenja approved for children under 12?

The initial U.S. approval covers patients aged 12 years and older. Use in younger children would require regulatory support for the relevant age group and dosing.

Can a generic company launch Joenja before 2030?

A generic company could file a patent challenge before 2030, but commercial launch would depend on orphan exclusivity, Orange Book patents, litigation outcomes, settlement terms, and FDA approval requirements.

What is the largest financial risk to Pharming from Joenja?

The largest risk is slower-than-expected diagnosis and patient adoption. Because the market is small, even a modest shortfall in diagnosed or reimbursed patients can materially reduce revenue forecasts.

References

  1. U.S. Food and Drug Administration. (2023). Joenja (leniolisib) prescribing information and approval announcement. https://www.fda.gov
  2. Lucas, C. L., Kuehn, H. S., Zhao, F., et al. (2014). Dominant-activating germline mutations in the gene encoding the PI3K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nature Immunology, 15(1), 88-97.
  3. Pharming Group N.V. (2024). Annual report 2023. https://www.pharming.com
  4. Pharming Group N.V. (2025). Annual report 2024 and full-year results. https://www.pharming.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.